LAB Q2 2022 Earnings — Standard BioTools Inc. Revenue & Financial Results | Market Cap Arena

LABStandard BioTools Inc.

$388M

Q2 2022 Earnings

Healthcare Medical - Devices

Income Statement

Revenue

$19M-39.5% YoY

Gross Profit

$4M23.6% margin

Operating Income

-$39M-205.4% margin

Net Income

-$64M-338.4% margin

EPS (Diluted)

$-0.82

QoQ Revenue Growth

-29.2%

Cash Flow

Operating Cash Flow

-$30M

Free Cash Flow

-$31M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$441M

Total Liabilities

$479M

Stockholders' Equity

-$37M

Cash & Equivalents

$74M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$19M	$31M	-39.5%
Gross Profit	$4M	$16M	-73.0%
Operating Income	-$39M	-$17M	-123.3%
Net Income	-$64M	-$17M	-270.6%

Revenue Segments

Product

$12M39%

Consumables

$10M30%

Service

$6M18%

Instruments

$3M8%

Product and Service, Other

$396,0001%

License

$396,0001%

Collaboration Revenue

$356,0001%

Geographic Segments

Americas

$9M50%

EMEA

$6M30%

Asia Pacific

$4M20%